[Full text] Pharmacokinetics and Bioequivalence Evaluation of Two Montelukast Sodi

Introduction

Montelukast sodium is a highly selective, type I, cysteinyl leukotriene receptor antagonist. Montelukast sodium has been shown to significantly improve the clinical symptoms of children with bronchial asthma by inhibiting the combination of cysteinyl leukotriene and its receptor, improving the inflammatory index of asthma and alleviating leukotriene-mediated bronchoconstriction, increased vascular permeability, and mucus secretion.^1,2

The combination of montelukast sodium and inhaled glucocorticoid has demonstrated synergistic and substitutive effects: the dosage of inhaled glucocorticoid can gradually be reduced through the continued use of the combination, allowing for the avoidance and reduction of local and systemic side effects associated with glucocorticoid use.^3–5

The montelukast sodium chewable tablet has been indicated as an effective drug for the prevention…